Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported the presentation of results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VELCADE and dexamethasone (VcD) to vincristine, adriamycin and dexamethasone (VAD). This study was conducted by the Intergroupe Francophone du Myelome (IFM) cooperative group and CHU Nantes and selected for an oral presentation at the American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, Ga., December 8-11, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

"The very high complete and near complete remission rate of 21 percent with this induction therapy significantly improved post-transplantation complete remission rates. This led to a decrease in patients requiring a second transplant," said Professor Jean-Luc Harousseau, M.D., Hospital Hotel- Dieu Nantes and Principal Investigator of the trial. "Historically, regimens used as induction therapy prior to stem cell transplantation (SCT) produced low complete remission rates and offered minimal incremental benefit post- transplantation."

Results from the large clinical trial were presented by Professor Harousseau:
-- As induction therapy prior to SCT, the VcD arm demonstrated a complete

remission (CR, including immunofixation positive and negative) rate of

21 percent compared to 8 percent with VAD (p<0.0001)

-- Of the 404 patients who proceeded to SCT, the VcD arm demonstrated a

post-transplantation complete remission (CR, including immunofixation

positive and negative) rate of 41 percent comp
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
2. Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy
3. Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma
4. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
5. HCV and HBV spreading more slowly among injection drug users in San Francisco
6. Microbiotic technology developed for microinjection of zebrafish embryos
7. Pill Equals Injection in Preventing Clots After Hip Replacement
8. Multiple corticosteroid injections in pregnant women may increase cerebral palsy
9. Consumer Safety Alert on Fat Dissolving Injections
10. MultiVu Video Feed: FDA Approves DORIBAX(TM) (doripenem for injection) for the Treatment of Complicated Intra-abdominal and Complicated Urinary Tract Infections
11. Ultrasound-guided injections help ease chronic Achilles tendon pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (PRWEB) September 17, 2014 ... Access Management (IdM/IAM) solutions and Boston Software ... their business partner relationship. Under the ... technology to automate functionality within its identity ... Software Systems provides healthcare automation platforms that ...
(Date:9/17/2014)... UK, September 17, 2014 The International Journal of ... opened up its archive of previously published content: after 24 ... A key aim of the IJS is to ... that by making these articles available to all will improve ... of IJS said, "The journal has always been ...
(Date:9/17/2014)... A recent study of 54,000 surgical patients ... these patients developed surgical site infections (SSIs), with 0.8% labeled ... average difference for each patient with an SSI and those ... by Marin Schweizer, PhD, of the Iowa City VA Health ... costs for the hospitals were 1.25 times more for patients ...
(Date:9/17/2014)... 2014 The probability of prostate cancer ... screening and examination, a healthy diet could decrease the ... Epicure with the Chef MDs, renowned Chef Vikram ... to prepare a delicious Fish Moilee. , Dr. Rusilko ... influence risk of prostate cancer, uncommonly found in Asian ...
(Date:9/17/2014)... Acceleratio Ltd., an innovative software ... 6.0 of Server Monitoring Toolkit , a ... reporting. It brings real-time server monitoring via a ... and enhanced features that significantly improve troubleshooting and ... provides agentless data collection, a user-friendly interface, and ...
Breaking Medicine News(10 mins):Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Three Ways to Minimize Costs Associated with Surgical Site Infections 2Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 2Health News:New Server Monitoring Toolkit v6 Brings Real-Time Windows Server Monitoring and New Server Reports 3
... BURLINGTON, N.J., Aug. 5 Most people over the age ... to focus on nearby objects. Although this age related phenomena is ... Kajita Clinic in Tokyo, Japan and published in March, 2009 has ... in older subjects (mean age of 53.9 +/- 5.1 years) with ...
... , , WASHINGTON, Aug. ... its latest report on effective emergency management for people with ... Association of Emergency Managers, 2009 National Conference on ... Corps at the Hyatt Regency Crystal City Hotel, 2799 ...
... , Goal to Distinguish Science Questions from Policy ... Advisory Committees Solely of Members with Relevant Scientific Expertise; Improve ... 5 A bipartisan panel of top scientific and regulatory ... federal agencies to make specific changes in the regulatory process ...
... , , CINCINNATI, Aug. 5 ... STRM ) today announced that, in an effort to further ... independent, non-management director as the Company,s Chairman of the Board. ... current independent member of the Company,s Board of Directors, as Chairman ...
... , , BOULDER, Colo., Aug. 5 ... Organic Center) strongly refute the claim made by Dr. Alan Dangour and ... important., Left unchallenged, the U.K. team,s study and Dr. Dangour,s remarks ... organic food. Among the multiple missteps in the FSA,s analysis are ...
... , , CARLSBAD, ... their DNA recovery product, GenSolve(TM), is enabling independent groups, from diverse ... for microarray based genomic analysis and Illumina iSelect based genotyping. , ... 2 :107 (16 June 2009) and BMC Genetics 2009, 10 ...
Cached Medicine News:Health News:The Reduction of Eye Fatigue Improves Vision in Older Subjects 2Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 2Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 3Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 4Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 5Health News:Bipartisan Panel of Industry, NGO and Academic Experts Proposes New Rules for Science in Federal Regulation 6Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 2Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 3Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 4Health News:Streamline Health Appoints Jon Phillips Chairman of the Board of Directors 5Health News:The Organic Center Refutes Misleading Nutritional Claims Made by United Kingdom's Food Standards Agency (FSA) in Agency Report on Health Value of Organic Foods 2Health News:GenVault's GenSolve(TM) Reagents Enable State-of-the-Art Genomic Analysis of Dried Blood Spots 2Health News:GenVault's GenSolve(TM) Reagents Enable State-of-the-Art Genomic Analysis of Dried Blood Spots 3
(Date:9/17/2014)... , Sept. 17, 2014  Trovagene, Inc., (NASDAQ: ... today that Alberto Bardelli , Ph.D., has joined ... the first to identify mutations in the kinase genes ... Currently, he is at the Department of Oncology, Torino ... Italy . "Alberto,s work ...
(Date:9/17/2014)...  Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), ... received an unsolicited, non-binding proposal from Endo International plc ... the outstanding shares of Auxilium common stock at a ... stock, subject to due diligence, financing and other conditions. ... received from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... , Sept. 17, 2014 Research ... "Global Breast Cancer Market 2014-2018" report to ... by the uncontrolled growth of cancerous cells in the ... however, male breast cancer is rare. Histologically, breast cancer ... cancer and other undifferentiated carcinoma. Ductal carcinoma is the ...
Breaking Medicine Technology:Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 2Cancer Geneticist, Alberto Bardelli, Ph.D., Joins Trovagene's Scientific Advisory Board 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 2Global Breast Cancer Market 2014-2018: Key Vendors are Astrazeneca, Eli Lilly and Company and F. Hoffmann-La Roche, Novartis and Sanofi-Aventis 3
... (OTC Bulletin Board: CGNH ) announced today that ... 2 Class B common stockholders a "Stockholder Questionnaire," which the ... count of the Company,s shares currently held in "street ... If you have not received the Stockholder Questionnaires via ...
... VILLAGE, Nev., March 8, 2011 PDL BioPharma, Inc. (PDL) (Nasdaq: ... rate for its 2.00% Convertible Senior Notes due February 15, 2012 ... 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection ... to all stockholders who own shares of PDL on March 8, ...
Cached Medicine Technology:CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires 2PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015 2
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: